^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CLDN18 fusion

    i
    Other names: CLDN18, Claudin-18, Surfactant, Pulmonary Associated Protein J, Surfactant Associated 5, SFTA5, SFTPJ
    Entrez ID:
    51208
    Related biomarkers:
    Expression
    Fusion
    7ms
    Mutation characteristics and molecular evolution of ovarian metastasis from gastric cancer and potential biomarkers for paclitaxel treatment. (PubMed, Nat Commun)
    Additionally, by analyzing the differential response to chemotherapy, we identify potential biomarkers, including SALL4, CCDC105, and CLDN18, for predicting the efficacy of paclitaxel treatment. Furthermore, we validate that CLDN18 fusion mutations improve tumor response to paclitaxel treatment in GC with ovarian metastasis in vitro and vivo.
    Journal
    |
    CLDN18 (Claudin 18) • SALL4 (Spalt Like Transcription Factor 4)
    |
    CLDN18 fusion
    |
    paclitaxel
    12ms
    First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors. (ASCO-GI 2024)
    No data analysis is available as of the submission deadline. Clinical trial information: NCT05862324.
    P1/2 data • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18.2 expression • CLDN18.2 positive • CLDN18 fusion
    |
    TAC101-Claudin18.2
    1year
    A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors (SITC 2023)
    2 expression levels will be based on retrospective analysis of data from Phase 1 in association with clinical efficacy. A Simon 2-stage design will be used to enroll ≤57 subjects in Group A and ≤22 subjects in Group C. Group B will be exploratory and will enroll ≤10 subjects with an opportunity of cohort enrichment based on clinical efficacy data.
    Clinical • P1/2 data • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18 fusion
    |
    TAC101-Claudin18.2
    1year
    TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (clinicaltrials.gov)
    P1/2, N=113, Recruiting, Triumvira Immunologics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • CLDN18 (Claudin 18) • BRCA (Breast cancer early onset)
    |
    EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation • CLDN18 fusion
    |
    albumin-bound paclitaxel • cyclophosphamide • TAC101-Claudin18.2